Adalta

Adalta EV/OCF

The EV/OCF (Enterprise Value to Operating Cash Flow) of Adalta (1AD.AX) as of Oct 20, 2026 is -1.72. In the previous year, EV/OCF (Enterprise Value to Operating Cash Flow) was -3.20 — a change of -46.17% (higher).

EV/OCF

-1.72

YoY

-46.17%

Last updated:

EV/OCF (Enterprise Value to Operating Cash Flow) of Adalta is 2026 -1.72 . EV/OCF (Enterprise Value to Operating Cash Flow) of Adalta was 2025 -3.20 . It decreases by -46.17% higher compared to the previous year.

The Adalta EV/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/OCF
Date
EV/OCF
Jan 1, 2019
-0.96 AUD
Jan 1, 2020
-1.32 AUD
Jan 1, 2021
-1.01 AUD
Jan 1, 2022
-1.04 AUD
Jan 1, 2023
-1.59 AUD
Jan 1, 2024
-1.62 AUD
Jan 1, 2025
-3.20 AUD
Jan 1, 2026
-1.72 AUD
The Adalta EV/OCF history
YEAREV/OCFYoY
-1.72-46.17%
-3.20+97.90%
-1.62+1.72%
-1.59+52.16%
-1.04+3.52%
-1.01-23.39%
-1.32+37.65%
-0.96-43.26%
-1.68+132.58%
-0.72-147.61%
1.52-123.66%
-6.43-2.89%
-6.62—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Adalta Stock analysis

What does Adalta do? AdAlta Ltd. operates as a biotechnology company that discovers, develops, and commercializes protein based therapeutics. The firm is engaged in the development of therapeutic products from its i-body platform. The firm has five active development programs ranging from discovery to Phase II clinical trials with applications in the fields of inflammation/fibrosis and immuno-oncology. Its lead product, AD-214, is an antibody therapeutic for the treatment of fibrotic diseases, including lung fibrosis (specifically Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Disease (ILD)), kidney fibrosis, eye fibrosis and some cancers. Chimeric Antigen Receptor (CAR) cell therapies involve modification of a patient’s immune cells (T cells, NK cells, macrophages and other) so that they produce a CAR on the cell surface that enables the patient’s immune system to recognize and kill diseased cells such as cancer. The company develops i-body enabled PET (i-PET) imaging agents for use in immuno-oncology. The company evaluates several CXCR4 i-bodies. Adalta is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Adalta stock

EV/OCF (Enterprise Value to Operating Cash Flow) of Adalta is -1.72 in 2026.

EV/OCF (Enterprise Value to Operating Cash Flow) of Adalta changed from -3.20 to -1.72, representing a -46.17% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/OCF (Enterprise Value to Operating Cash Flow) Adalta since 2006 – with annual values, charts, and detailed analysis.

EV/OCF compares enterprise value to operating cash flow, measuring how much investors pay per unit of cash generated from operations.

To evaluate EV/OCF (Enterprise Value to Operating Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/OCF (Enterprise Value to Operating Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/OCF (Enterprise Value to Operating Cash Flow)'s Adalta with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Adalta

All Key Metrics — Adalta